Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

345 ARTÍCULOS , VIENDO DEL 121 AL 135

Natural products for Alzheimer's disease therapy: basic and application

Xiao J, Tundis R.

J Pharm Pharmacol. 2013 Dec;65(12):1679-80. doi: 10.1111/jphp.12186.

Nature as a source of metabolites with cholinesterase-inhibitory activity: an approach to Alzheimer's disease treatment

Pinho BR, Ferreres F, Valentão P, Andrade PB.

J Pharm Pharmacol. 2013 Dec;65(12):1681-700. doi: 10.1111/jphp.12081. Epub 2013 May 16.

Alkaloids as a source of potential anticholinesterase inhibitors for the treatment of Alzheimer's disease

Konrath EL, Passos Cdos S, Klein LC Jr, Henriques AT.

J Pharm Pharmacol. 2013 Dec;65(12):1701-25. doi: 10.1111/jphp.12090. Epub 2013 Jun 20.

Berberis aetnensis and B. libanotica: a comparative study on the chemical composition, inhibitory effect on key enzymes linked to Alzheimer's disease and antioxidant activity

Bonesi M, Loizzo MR, Conforti F, Passalacqua NG, Saab A, Menichini F, Tundis R.

J Pharm Pharmacol. 2013 Dec;65(12):1726-35. doi: 10.1111/jphp.12172. Epub 2013 Nov 6.

Profile of gantenerumab and its potential in the treatment of Alzheimer's disease

Novakovic D, Feligioni M, Scaccianoce S, Caruso A, Piccinin S, Schepisi C, Errico F, Mercuri NB, Nicoletti F, Nisticò R.

Drug Des Devel Ther. 2013 Nov 13;7:1359-64. doi: 10.2147/DDDT.S53401. eCollection 2013.

[Present and future of the tau dementia therapy]

Takashima A.

Rinsho Shinkeigaku. 2013;53(11):1040-2. doi: 10.5692/clinicalneurol.53.1040.

[Molecular targeting and translational research for new therapeutic strategies on Alzheimer's disease]

Takata K.

Yakugaku Zasshi. 2013;133(12):1389-99. doi: 10.1248/yakushi.13-00219.

Disease-modifying drugs in Alzheimer's disease

Ghezzi L, Scarpini E, Galimberti D.

Drug Des Devel Ther. 2013 Dec 6;7:1471-8. doi: 10.2147/DDDT.S41431.

Iron and aluminum in Alzheimer's disease

Di Lorenzo F, Di Lorenzo B.

Neuro Endocrinol Lett. 2013;34(6):504-7.

[Cyclooxygenases, lipoxygenases, their targeted drugs and the prevention of Alzheimer's disease]

Shen JN, Xu LX, Wang R.

Yao Xue Xue Bao. 2013 Dec;48(12):1743-54.

[Proposal of endogenous anticholinergic hypothesis in Alzheimer disease]

Hori K, Konishi K, Akita R, Tani M, Tomioka H, Kitajima Y, Yokoyama S, Azuma K, Ikuse D, Akashi N, Yuda H, Hachisu M.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2013 Jun;33(3):117-26.

Rivastigmine in the treatment of hypersexuality in Alzheimer disease

Canevelli M, Talarico G, Tosto G, Troili F, Lenzi GL, Bruno G.

Alzheimer Dis Assoc Disord. 2013 Jul-Sep;27(3):287-8. doi: 10.1097/WAD.0b013e31825c85ae.

Alzheimer's disease and the "Valley Of Death": not enough guidance from human brain tissue?

Beach TG.

J Alzheimers Dis. 2013;33 Suppl 1:S219-33. doi: 10.3233/JAD-2012-129020.

Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's disease

Nunes MA, Viel TA, Buck HS.

Curr Alzheimer Res. 2013 Jan;10(1):104-7. doi: 10.2174/1567205011310010014.

Synaptotoxic amyloid-β oligomers: a molecular basis for the cause, diagnosis, and treatment of Alzheimer's disease?

Klein WL.

J Alzheimers Dis. 2013;33 Suppl 1:S49-65. doi: 10.3233/JAD-2012-129039.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias